膀胱尿路上皮癌中PD-L1和PD-L2的表达及临床意义

目的 探讨膀胱尿路上皮癌(urothelial bladder cancer,UBC)中程序性死亡配体-1(programmed death-ligand 1,PD-L1)以及程序性死亡配体-2(programmed death-ligand 2,PD-L2)的表达及临床意义.方法 采用免疫组化法检测58例UBC组织中...

Expression of PD-L1 and PD-L2 in urothelial bladder cancer and their clinicopathological significance

Purpose To investigate the expression and clinicopathological significance of programmed death-ligand 1(PD-L1)and programmed death-ligand 2(PD-L2)in urothelial bladder cancer(UBC).Methods Immunohistochemistry was used to determine the expression levels of PD-L1 and PD-L2 in tissue microarrays containing 58 cases of UBC.The relationships between the expression levels of PD-L1 and PD-L2 and clinicopathological features of UBC were also analyzed.Results The expression levels of PD-L1 on tumor cells(TC)in high-grade UBC and pT2-pT4 tumors were higher than that in low-grade UBC and pTa-pT1 tumors(all P<0.05 at cut-off points of 1%,10%and 50%).At a cut-off of 5%,the expression levels of PD-L1 on tumor-infiltrating immune cells(TIIC)in high-grade tumors and pT2-pT4 tumors were higher than that in low-grade tumors and pTa-pT1 tumors(both P<0.05).At a cut-off of 10%,the expression levels of PD-L1 on TIIC in pT2-pT4 tumors were higher than that in pTa-pT1 tumors(P=0.014).The expression levels of PD-L2 on TC were not associated with the clinicopathological parameters such as histological grade and pT stage of UBC(all P>0.05).At a cut-off of 50%,the expression levels of PD-L2 on TIIC in pT2-pT4 tumors were higher than that in pTa-pT1 tumors(P=0.044).The expression status of PD-L1 and PD-L2 on TC did not correlate with the overall survival(OS)of UBC patients(all P>0.05).At a cut-off of 5%,patients with high PD-L1 expression on TIIC had shortened OS compared with those with low expression of PD-L1 on TIIC(P=0.011).The expression status of PD-L2 on TIIC did not correlate with the OS of UBC patients(P>0.05).Conclusion PD-L1 and PD-L2 are often abnormally expressed in UBC tumor cells and TIIC.Evaluating the expression status of PD-L1 and PD-L2 in UBC may provide the basis for immunotherapy.